Literature DB >> 23774257

Retention of structure, antigenicity, and biological function of pneumococcal surface protein A (PspA) released from polyanhydride nanoparticles.

Shannon L Haughney1, Latrisha K Petersen, Amy D Schoofs, Amanda E Ramer-Tait, Janice D King, David E Briles, Michael J Wannemuehler, Balaji Narasimhan.   

Abstract

Pneumococcal surface protein A (PspA) is a choline-binding protein which is a virulence factor found on the surface of all Streptococcus pneumoniae strains. Vaccination with PspA has been shown to be protective against a lethal challenge with S. pneumoniae, making it a promising immunogen for use in vaccines. Herein the design of a PspA-based subunit vaccine using polyanhydride nanoparticles as a delivery platform is described. Nanoparticles based on sebacic acid (SA), 1,6-bis-(p-carboxyphenoxy)hexane (CPH) and 1,8-bis-(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG), specifically 50:50 CPTEG:CPH and 20:80 CPH:SA, were used to encapsulate and release PspA. The protein released from the nanoparticle formulations retained its primary and secondary structure as well as its antigenicity. The released PspA was also biologically functional based on its ability to bind to apolactoferrin and prevent its bactericidal activity against Escherichia coli. When the PspA nanoparticle formulations were administered subcutaneously to mice they elicited a high titer and high avidity anti-PspA antibody response. Together these studies provide a framework for the rational design of a vaccine against S. pneumoniae based on polyanhydride nanoparticles.
Copyright © 2013 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Nanoparticle; Pneumococcal surface protein A; Polyanhydride; Streptococcus pneumoniae; Vaccine

Mesh:

Substances:

Year:  2013        PMID: 23774257      PMCID: PMC3777629          DOI: 10.1016/j.actbio.2013.06.006

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  53 in total

1.  Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1.

Authors:  William M Gwinn; Shaun M Kirwan; Sheena H Wang; Kathleen A Ashcraft; Neil L Sparks; Catherine R Doil; Tom G Tlusty; Leslie S Casey; Susan K Hollingshead; David E Briles; Richard S Dondero; Anthony J Hickey; W Michael Foster; Herman F Staats
Journal:  Vaccine       Date:  2010-08-17       Impact factor: 3.641

2.  Protein stability in the presence of polymer degradation products: consequences for controlled release formulations.

Authors:  Amy S Determan; Jennifer H Wilson; Matt J Kipper; Michael J Wannemuehler; Balaji Narasimhan
Journal:  Biomaterials       Date:  2006-02-28       Impact factor: 12.479

3.  Microphase separation in bioerodible copolymers for drug delivery.

Authors:  E Shen; R Pizsczek; B Dziadul; B Narasimhan
Journal:  Biomaterials       Date:  2001-02       Impact factor: 12.479

4.  Gold nanoparticles as carriers for a synthetic Streptococcus pneumoniae type 14 conjugate vaccine.

Authors:  Dodi Safari; Marco Marradi; Fabrizio Chiodo; Huberta A Th Dekker; Yulong Shan; Roberto Adamo; Stefan Oscarson; Ger T Rijkers; Martina Lahmann; Johannis P Kamerling; Soledad Penadés; Harm Snippe
Journal:  Nanomedicine (Lond)       Date:  2012-05       Impact factor: 5.307

5.  Regions of PspA/EF3296 best able to elicit protection against Streptococcus pneumoniae in a murine infection model.

Authors:  Hazeline Roche; Anders Håkansson; Susan K Hollingshead; David E Briles
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

6.  Encapsulation into amphiphilic polyanhydride microparticles stabilizes Yersinia pestis antigens.

Authors:  Brenda Carrillo-Conde; Elise Schiltz; Jing Yu; F Chris Minion; Gregory J Phillips; Michael J Wannemuehler; Balaji Narasimhan
Journal:  Acta Biomater       Date:  2010-02-01       Impact factor: 8.947

7.  Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection.

Authors:  Adriana T Moreno; Maria Leonor S Oliveira; Daniela M Ferreira; Paulo L Ho; Michelle Darrieux; Luciana C C Leite; Jorge M C Ferreira; Fabiana C Pimenta; Ana Lúcia S S Andrade; Eliane N Miyaji
Journal:  Clin Vaccine Immunol       Date:  2010-01-20

8.  Truncated Streptococcus pneumoniae PspA molecules elicit cross-protective immunity against pneumococcal challenge in mice.

Authors:  R C Tart; L S McDaniel; B A Ralph; D E Briles
Journal:  J Infect Dis       Date:  1996-02       Impact factor: 5.226

9.  Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases.

Authors:  Bret D Ulery; Devender Kumar; Amanda E Ramer-Tait; Dennis W Metzger; Michael J Wannemuehler; Balaji Narasimhan
Journal:  PLoS One       Date:  2011-03-03       Impact factor: 3.240

10.  Impact of the 7-valent pneumococcal conjugate vaccine on the incidence of childhood pneumonia.

Authors:  M A Elemraid; S P Rushton; M D F Shirley; M F Thomas; D A Spencer; K M Eastham; F Hampton; R Gorton; K Pollard; A R Gennery; J E Clark
Journal:  Epidemiol Infect       Date:  2012-10-19       Impact factor: 2.451

View more
  23 in total

1.  Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague.

Authors:  Danielle A Wagner; Sean M Kelly; Andrew C Petersen; Nathan Peroutka-Bigus; Ross J Darling; Bryan H Bellaire; Michael J Wannemuehler; Balaji Narasimhan
Journal:  Acta Biomater       Date:  2019-10-11       Impact factor: 8.947

2.  A single dose polyanhydride-based nanovaccine against paratuberculosis infection.

Authors:  Akanksha Thukral; Kathleen Ross; Chungyi Hansen; Yashdeep Phanse; Balaji Narasimhan; Howard Steinberg; Adel M Talaat
Journal:  NPJ Vaccines       Date:  2020-02-14       Impact factor: 7.344

3.  Neuronal protection against oxidative insult by polyanhydride nanoparticle-based mitochondria-targeted antioxidant therapy.

Authors:  Timothy M Brenza; Shivani Ghaisas; Julia E Vela Ramirez; Dilshan Harischandra; Vellareddy Anantharam; Balaraman Kalyanaraman; Anumantha G Kanthasamy; Balaji Narasimhan
Journal:  Nanomedicine       Date:  2016-10-19       Impact factor: 5.307

4.  The effect of polyanhydride chemistry in particle-based cancer vaccines on the magnitude of the anti-tumor immune response.

Authors:  Emad I Wafa; Sean M Geary; Jonathan T Goodman; Balaji Narasimhan; Aliasger K Salem
Journal:  Acta Biomater       Date:  2017-01-04       Impact factor: 8.947

5.  pH-Responsive Microencapsulation Systems for the Oral Delivery of Polyanhydride Nanoparticles.

Authors:  Lindsey A Sharpe; Julia E Vela Ramirez; Olivia M Haddadin; Kathleen A Ross; Balaji Narasimhan; Nicholas A Peppas
Journal:  Biomacromolecules       Date:  2018-02-21       Impact factor: 6.988

6.  Safety and biocompatibility of carbohydrate-functionalized polyanhydride nanoparticles.

Authors:  Julia E Vela-Ramirez; Jonathan T Goodman; Paola M Boggiatto; Rajarshi Roychoudhury; Nicola L B Pohl; Jesse M Hostetter; Michael J Wannemuehler; Balaji Narasimhan
Journal:  AAPS J       Date:  2014-11-25       Impact factor: 4.009

7.  Evaluation of Protective Efficacy of Selected Immunodominant B-Cell Epitopes within Virulent Surface Proteins of Streptococcus pneumoniae.

Authors:  Theodora Papastamatiou; John G Routsias; Olga Koutsoni; Eleni Dotsika; Athanassios Tsakris; Vana Spoulou
Journal:  Infect Immun       Date:  2018-02-20       Impact factor: 3.441

8.  Comparison of four adjuvants revealed the strongest protection against lethal pneumococcal challenge following immunization with PsaA-PspA fusion protein and AS02 as adjuvant.

Authors:  Xiaorui Chen; Bo Li; Jinfei Yu; Yue Zhang; Zujian Mo; Tiejun Gu; Wei Kong; Yong Zhang; Yongge Wu
Journal:  Med Microbiol Immunol       Date:  2019-02-01       Impact factor: 3.402

9.  Single Dose of a Polyanhydride Particle-Based Vaccine Generates Potent Antigen-Specific Antitumor Immune Responses.

Authors:  Emad I Wafa; Sean M Geary; Kathleen A Ross; Jonathan T Goodman; Balaji Narasimhan; Aliasger K Salem
Journal:  J Pharmacol Exp Ther       Date:  2018-10-25       Impact factor: 4.030

10.  Polyanhydride Nanovaccines Induce Germinal Center B Cell Formation and Sustained Serum Antibody Responses.

Authors:  Julia E Vela Ramirez; Lorraine T Tygrett; Jihua Hao; Habtom H Habte; Michael W Cho; Neil S Greenspan; Thomas J Waldschmidt; Balaji Narasimhan
Journal:  J Biomed Nanotechnol       Date:  2016-06       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.